NDMA urges "substantial evidence" standard of judicial review for FDA rulemaking.
This article was originally published in The Tan Sheet
Executive Summary
"SUBSTANTIAL EVIDENCE" STANDARD OF JUDICIAL REVIEW FOR FDA RULEMAKING is urged by the Nonprescription Drug Manufacturers Association in written testimony to the House Commerce Committees/health subcommittee. The testimony was part of a May 1-2 hearing on FDA reform legislation.